Micaela Hernberg

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.3K citations · Full text

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 364 citations · Full text

Surgical Oncology, Medicine, Melanoma +8

Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

Paolo A. Ascierto, Georgina V. Long, Caroline Robert et al. · JAMA Oncology · 2018 · 330 citations · Full text

Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma

Caroline Robert, Georgina V. Long, Benjamin Brady et al. · Journal of Clinical Oncology · 2020 · 208 citations · Full text

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

Johan Hansson, Steinar Aamdal, Lars Bastholt et al. · The Lancet Oncology · 2011 · 96 citations

Nordic Ifn Trial, Medicine, Randomised Phase 3 +7